...
机译:NemO肽通过阻断NF-κB活化来抑制胰腺导管腺癌的生长
Department of Gastrointestinal Surgery Beijing Tsinghua Changgung Hospital School of Clinical;
Department of Head and Neck Sun Yat-sen University Cancer Center;
Department of Molecular and Cellular Oncology The University of Texas MD Anderson Cancer Center;
Department of Molecular and Cellular Oncology The University of Texas MD Anderson Cancer Center;
Department of Molecular and Cellular Oncology The University of Texas MD Anderson Cancer Center;
Department of Molecular and Cellular Oncology The University of Texas MD Anderson Cancer Center;
Department of Molecular and Cellular Oncology The University of Texas MD Anderson Cancer Center;
Department of Molecular and Cellular Oncology The University of Texas MD Anderson Cancer Center;
Department of Molecular and Cellular Oncology The University of Texas MD Anderson Cancer Center;
Department of Molecular and Cellular Oncology The University of Texas MD Anderson Cancer Center;
Department of Molecular and Cellular Oncology The University of Texas MD Anderson Cancer Center;
Department of Molecular and Cellular Oncology The University of Texas MD Anderson Cancer Center;
Department of Molecular and Cellular Oncology The University of Texas MD Anderson Cancer Center;
Pancreatic cancer; Targeted therapy; NF-κB; IKKγ; Gemcitabine;
机译:NemO肽通过阻断NF-κB活化来抑制胰腺导管腺癌的生长
机译:Kras G12D诱导的IL-1α和p62前馈环激活IKK2 /β/NF-κB活化是胰管腺癌发展的必要条件。
机译:降压药作为新型抗肿瘤药:胰导管腺癌中的血管紧张素-I转换酶抑制剂和血管紧张素II 1型受体阻滞剂。
机译:开发一种新型的可生物降解的纳米树纹平台,用于克服治疗胰腺导管腺癌(PDAC)的挑战
机译:HuR调节聚ADP核糖糖水解酶:对胰腺导管腺癌细胞中PARP抑制剂功效的影响。
机译:NEMO肽通过阻断NF-κB的激活抑制胰腺导管腺癌的生长
机译:NemO肽通过阻断NF-κB活化来抑制胰腺导管腺癌的生长